Last reviewed · How we verify
Levodopa Benserazide Teva Italia
Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while benserazide inhibits peripheral conversion of levodopa to prevent side effects.
Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while benserazide inhibits peripheral conversion of levodopa to prevent side effects. Used for Parkinson's disease.
At a glance
| Generic name | Levodopa Benserazide Teva Italia |
|---|---|
| Sponsor | IRCCS San Raffaele Roma |
| Drug class | Dopamine precursor with peripheral decarboxylase inhibitor |
| Target | Aromatic amino acid decarboxylase (inhibited by benserazide); dopamine receptors (target of levodopa-derived dopamine) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Levodopa crosses the blood-brain barrier and is converted to dopamine by aromatic amino acid decarboxylase, restoring dopamine levels in Parkinson's disease patients. Benserazide is a peripheral decarboxylase inhibitor that prevents premature conversion of levodopa to dopamine outside the central nervous system, allowing more levodopa to reach the brain and reducing peripheral adverse effects like nausea and cardiovascular symptoms.
Approved indications
- Parkinson's disease
Common side effects
- Nausea
- Dyskinesia
- Orthostatic hypotension
- Dizziness
- Hallucinations
- Insomnia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levodopa Benserazide Teva Italia CI brief — competitive landscape report
- Levodopa Benserazide Teva Italia updates RSS · CI watch RSS
- IRCCS San Raffaele Roma portfolio CI